×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Myeloma
Feature Video
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
The Multiple Myeloma Research Foundation
"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek.
Jason M. Broderick
The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.
Ellen Miller-Sonet
Treating people with cancer requires the coordination of complex care, and adding a clinical trial to the mix can pose more challenges.
Kristie L. Kahl
A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.
Kristie L. Kahl
Preliminary findings showed that Revlimid (lenalidomide) significantly prolonged progression-free survival compared with observation in patients with smoldering multiple myeloma.
OncLive Staff
The Food and Drug Administration has granted a priority review to a new drug application for selinexor (KPT-330) for the treatment of patients with penta-refractory multiple myeloma.
Jason M. Broderick
The Food and Drug Admnistration has approved a once-weekly dosing option of Kyprolis (carfilzomib) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.
Katie Kosko and Brielle Urciuoli
September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:
Katie Kosko
A 16-member team, including five patients with multiple myeloma, hiked through Iceland to raise money for disease research in hopes of finding a cure.